FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912127715> ?p ?o ?g. }

• W2912127715 endingPage "S386" @default.
• W2912127715 startingPage "S386" @default.
• W2912127715 abstract "CT-P13, the first biosimilar to infliximab (IFX), has an efficacy and tolerance profile comparable to IFX originator, at a lower cost. Physicians are thus strongly encouraged to propose a biosimilar. However, for patients, the switch from IFX originator to a biosimilar is not always accepted. The aim of this study was to evaluate the impact of patient education (PE) on the acceptance of a switch from IFX originator to biosimilar in IBD patients treated with IFX originator. In a monocentric prospective study, all IBD adult patients treated with IFX originator between June 2017 and June 2018, in clinical remission for at least 6 months, were asked to complete a questionnaire specifically designed for this study, to assess their knowledge on biosimilars and their acceptance of a switching strategy. Patients had the choice whether or not to accept the switch, with or without PE. The primary endpoint was the percentage of patients who accepted the switch, after receiving a PE session due to an initial refusal. Secondary endpoints were the evaluation of patient knowledge and feeling regarding biosimilar treatment; clinical remission, based on the Harvey–Bradshaw Index (score < 4) for CD and the partial Mayo score (< 2) for UC; biological remission: C reactive protein (N<5 mg/l) and faecal calprotectin (N<150 μg/g stool) and immunogenicity after the switch, trough levels of IFX (TLI) and anti-IFX antibodies (ATI). 86 patients (median age: 44 years [19–79]) were included (36% UC and 64% CD). The switch was initially refused by 47% of patients. In this subgroup, 78% agreed to participate in an educational interview with the PE nurse; 68% finally accepted the switch. At Week 16, the persistence on biosimilar was 91%. At weeks 0, 8 and 16, respectively, Mayo score was 0.68 ± 0.69, 0.81 ± 0.95 and 0.57 ± 0.76 (p = 0.733) and Harvey–Bradshaw score was 0.88 ± 1.70, 1.95 ± 2.27 and 2.14 ± 2.36 (p = 0.134); CRP was 2.92 ± 4.52, 3.48 ± 5.99 and 4.33 ± 10.82 (p = 0.724); faecal calprotectin was 291 ± 402, 418 ± 596 and 427 ± 459 (p = 0.745); TLI was 5.00 ± 3.98, 4.81 ± 3.97 and 4.44 ± 3.34 (p = 0.642); no patients had immunisation after the switch; IBDQ was 182.61 ± 28 at W0 and 175 ± 34 for at W16 (p = 0.494). The evaluation on the knowledge of biosimilars at W0 showed that 77% of patients had never heard about it, 85% were in favour of the switch and 61% expressed fears about their use. At Week 16, the same evaluation showed that 84% of patients said they knew about biosimilars, 93% were in favour of the switch and 39% were still concerned about their use. This study confirms the safety of switching infliximab by CT-P13 and demonstrates for the first time that PE plays a key role in switch acceptance by patients." @default.
• W2912127715 created "2019-02-21" @default.
• W2912127715 creator A5018182258 @default.
• W2912127715 creator A5020935740 @default.
• W2912127715 creator A5024211406 @default.
• W2912127715 creator A5031172442 @default.
• W2912127715 creator A5042386776 @default.
• W2912127715 creator A5064276019 @default.
• W2912127715 date "2019-01-25" @default.
• W2912127715 modified "2023-09-27" @default.
• W2912127715 title "P544 Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study" @default.
• W2912127715 doi "https://doi.org/10.1093/ecco-jcc/jjy222.668" @default.
• W2912127715 hasPublicationYear "2019" @default.
• W2912127715 type Work @default.
• W2912127715 sameAs 2912127715 @default.
• W2912127715 citedByCount "3" @default.
• W2912127715 countsByYear W29121277152019 @default.
• W2912127715 countsByYear W29121277152021 @default.
• W2912127715 countsByYear W29121277152023 @default.
• W2912127715 crossrefType "journal-article" @default.
• W2912127715 hasAuthorship W2912127715A5018182258 @default.
• W2912127715 hasAuthorship W2912127715A5020935740 @default.
• W2912127715 hasAuthorship W2912127715A5024211406 @default.
• W2912127715 hasAuthorship W2912127715A5031172442 @default.
• W2912127715 hasAuthorship W2912127715A5042386776 @default.
• W2912127715 hasAuthorship W2912127715A5064276019 @default.
• W2912127715 hasBestOaLocation W29121277151 @default.
• W2912127715 hasConcept C126322002 @default.
• W2912127715 hasConcept C17991360 @default.
• W2912127715 hasConcept C203092338 @default.
• W2912127715 hasConcept C2777138892 @default.
• W2912127715 hasConcept C535046627 @default.
• W2912127715 hasConcept C59491497 @default.
• W2912127715 hasConcept C71924100 @default.
• W2912127715 hasConceptScore W2912127715C126322002 @default.
• W2912127715 hasConceptScore W2912127715C17991360 @default.
• W2912127715 hasConceptScore W2912127715C203092338 @default.
• W2912127715 hasConceptScore W2912127715C2777138892 @default.
• W2912127715 hasConceptScore W2912127715C535046627 @default.
• W2912127715 hasConceptScore W2912127715C59491497 @default.
• W2912127715 hasConceptScore W2912127715C71924100 @default.
• W2912127715 hasIssue "Supplement_1" @default.
• W2912127715 hasLocation W29121277151 @default.
• W2912127715 hasOpenAccess W2912127715 @default.
• W2912127715 hasPrimaryLocation W29121277151 @default.
• W2912127715 hasRelatedWork W2025398922 @default.
• W2912127715 hasRelatedWork W2549411889 @default.
• W2912127715 hasRelatedWork W2735084959 @default.
• W2912127715 hasRelatedWork W2900514407 @default.
• W2912127715 hasRelatedWork W2912127715 @default.
• W2912127715 hasRelatedWork W2971987621 @default.
• W2912127715 hasRelatedWork W3043102397 @default.
• W2912127715 hasRelatedWork W3044159591 @default.
• W2912127715 hasRelatedWork W4283661824 @default.
• W2912127715 hasRelatedWork W4321330688 @default.
• W2912127715 hasVolume "13" @default.
• W2912127715 isParatext "false" @default.
• W2912127715 isRetracted "false" @default.
• W2912127715 magId "2912127715" @default.
• W2912127715 workType "article" @default.